Key result
Infection rates for intrathecal drug delivery devices varied from 2.5% to 9.0% in clinical studies, and adherence to established surgical site infection guidelines may reduce their incidence.
Why the study?
What are the rates, risk factors, and management strategies for infections associated with intrathecal drug delivery and spinal cord stimulation systems?
What are the rates, risk factors, and management strategies for infections associated with intrathecal drug delivery and spinal cord stimulation systems?
Answers are grounded in this paper and cite their sources.
Device-related infections are a serious complication of intrathecal drug delivery and spinal cord stimulation systems, with infection rates ranging from 2.5% to 9.0% in clinical studies.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Follett et al. (2004) conducted a review in Intrathecal drug delivery and spinal cord stimulation system infections. Intrathecal drug delivery and spinal cord stimulation systems was evaluated on Device-related infection rates. Infection rates for intrathecal drug delivery devices varied from 2.5% to 9.0% in clinical studies, and adherence to established surgical site infection guidelines may reduce their incidence.
Synapse has enriched 10 related papers. Consider them for comparative context: